
AMARIN CORP PLC -ADR
AMRNNASDAQTrading Snapshot
- Day Range
- $13.84 โ $14.07
- 52-Week Range
- $12.96 โ $20.90
- Volume
- $3.25B
- Avg Volume
- $3.51B
- Shares Outstanding
- 422.5M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $214M
- Last Q Revenue
- $42M
- P/E Ratio
- โ
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-0.07
- Dividend Yield
- โ
Why Investors Own AMRN
- โHigh-growth profile โ revenue up +47.2% YoY with expanding US Equity exposure.
- โHealthy economics โ 44% gross margin and 6% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AMARIN CORP PLC -ADR
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsDevin SullivanAaron Berg - CEO, President &...

Amarin Posts Surprise Q2 Profit on Cost Discipline, Shares Rise Pre-Market (NASDAQ:AMRN)
Amarin Q2 results: revenue miss at $42.2M but surprise $0.04 adjusted EPS beat. Cost cuts drive positive cash flow, shares up 1.7%.
Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $42.211 million which missed the analyst consensus estimate of $44.550 million by 5.25 percent. This is a 41.97 percent decrease over sales of $72.740 million the